-- Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a ...

For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

October 27, 2006 — Health Canada has approved a new indication for perindopril erbumine, allowing its use to reduce the risk for cardiovascular adverse events and mortality in patients with stable ...

Eagerly awaited final results of the five-year, 19,000-patient ASCOT study demonstrate that the combination of the newer blood-pressure-lowering drugs – Pfizer’s calcium channel blocker Norvasc ...

A new sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)(1), presented during a late breaking clinical trial session ...

This leaflet answers some common questions about COVERSYL PLUS. It does not contain all the available information about this medicine. Reading this leaflet does not take the place of talking to your ...

Aug. 25, 2005 — The U.S. Food and Drug Administration (FDA) has approved once-daily perindopril erbumine tablets for use alone or in combination with concurrent therapy to reduce the risk of ...

France’s Servier says it is disappointed by the decision of the UK High Court to award damages to Canadian generic drugmaker Apotex of £17.5 million in a patent dispute concerning its blood-pressure ...